Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas J Moore

Showing results (31-40 of 75) with videos related to

Pageof 8
Sort By:
JAMA Oncology|September 23, 2021
Medicare Expenditures of Atezolizumab for a Withdrawn Accelerated Approved IndicationJeromie Ballreich, Charles Bennet, Thomas J Moore, et al.
JAMA Internal Medicine|September 29, 2018
Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016Thomas J Moore, Hanzhe Zhang, Gerard Anderson, et al.
The New England Journal of Medicine|September 21, 2017
The Fate of FDA Postapproval StudiesSteven Woloshin, Lisa M Schwartz, Brian White, et al.
Clinical Trials (London, England)|March 3, 2020
Estimated costs of pivotal trials for U.S. Food and Drug Administration-approved cancer drugs, 2015-2017Emily Han-Chung Hsiue, Thomas J Moore, G Caleb Alexander
Clinical Orthopaedics and Related Research|December 31, 2011
CD4 count is associated with postoperative infection in patients with orthopaedic trauma who are HIV positiveGeorge N Guild, Thomas J Moore, Whitney Barnes, et al.
BMJ Open|June 14, 2020
Variation in the estimated costs of pivotal clinical benefit trials supporting the US approval of new therapeutic agents, 2015-2017: a cross-sectional studyThomas J Moore, James Heyward, Gerard Anderson, et al.
Drug Safety|April 25, 2009
Iatrogenic effects of COX-2 inhibitors in the US population: findings from the Medical Expenditure Panel SurveyRhema Vaithianathan, Peter M Hockey, Thomas J Moore, et al.
Pediatrics|November 5, 2002
Reported adverse drug events in infants and children under 2 years of ageThomas J Moore, Sheila R Weiss, Sigal Kaplan, et al.
Pharmacotherapy|June 6, 2022
Safety and effectiveness of NMDA receptor antagonists for depression: A multidisciplinary reviewThomas J Moore, Abdallah Alami, G Caleb Alexander, et al.
Pharmaceutical Medicine|March 18, 2020
US Food and Drug Administration Safety Advisories and Reporting to the Adverse Event Reporting System (FAERS)Thomas J Moore, Richard L Morrow, Colin R Dormuth, et al.
Pageof 8

Showing results (31-40 of 75) with videos related to

Sort By:
Pageof 8
JAMA Oncology|September 23, 2021
Medicare Expenditures of Atezolizumab for a Withdrawn Accelerated Approved IndicationJeromie Ballreich, Charles Bennet, Thomas J Moore, et al.
JAMA Internal Medicine|September 29, 2018
Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016Thomas J Moore, Hanzhe Zhang, Gerard Anderson, et al.
The New England Journal of Medicine|September 21, 2017
The Fate of FDA Postapproval StudiesSteven Woloshin, Lisa M Schwartz, Brian White, et al.
Clinical Trials (London, England)|March 3, 2020
Estimated costs of pivotal trials for U.S. Food and Drug Administration-approved cancer drugs, 2015-2017Emily Han-Chung Hsiue, Thomas J Moore, G Caleb Alexander
Clinical Orthopaedics and Related Research|December 31, 2011
CD4 count is associated with postoperative infection in patients with orthopaedic trauma who are HIV positiveGeorge N Guild, Thomas J Moore, Whitney Barnes, et al.
BMJ Open|June 14, 2020
Variation in the estimated costs of pivotal clinical benefit trials supporting the US approval of new therapeutic agents, 2015-2017: a cross-sectional studyThomas J Moore, James Heyward, Gerard Anderson, et al.
Drug Safety|April 25, 2009
Iatrogenic effects of COX-2 inhibitors in the US population: findings from the Medical Expenditure Panel SurveyRhema Vaithianathan, Peter M Hockey, Thomas J Moore, et al.
Pediatrics|November 5, 2002
Reported adverse drug events in infants and children under 2 years of ageThomas J Moore, Sheila R Weiss, Sigal Kaplan, et al.
Pharmacotherapy|June 6, 2022
Safety and effectiveness of NMDA receptor antagonists for depression: A multidisciplinary reviewThomas J Moore, Abdallah Alami, G Caleb Alexander, et al.
Pharmaceutical Medicine|March 18, 2020
US Food and Drug Administration Safety Advisories and Reporting to the Adverse Event Reporting System (FAERS)Thomas J Moore, Richard L Morrow, Colin R Dormuth, et al.
Pageof 8